EFAVIRENZ

Efavirenz is a non‑nucleoside reverse transcriptase inhibitor used in HIV therapy. It blocks viral replication. Side effects include vivid dreams, dizziness, rash, and mood changes.

SKU: ad6c582d6047 Category: Tag:

Product Description


Mechanism of Action

Efavirenz is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) that binds an allosteric pocket on HIV‑1 reverse transcriptase. This induces conformational changes that block polymerase activity, inhibiting viral DNA synthesis. It displays potent antiviral activity but has CNS‑penetrant effects due to high lipophilicity.

Benefits and Advantages

Used in NNRTI‑mechanism studies, HIV‑polymerase allosteric‑inhibition assays, resistance‑mutation modelling, and antiviral‑SAR research.

Side Effects and Risks

Risks include CNS effects (vivid dreams, dizziness), hepatotoxicity, rash, psychiatric symptoms and teratogenicity risk. Handle with antiviral‑compound precautions.

Datasheet


Molecular Formula

C14H9ClF3NO2

Molecular Weight

315.67 g/mol

CAS Number

154598-52-4

Storage Condition

Commercially available efavirenz capsules and tablets should be stored at a controlled room temperature of 25 °C, but may be exposed to temperatures ranging from 15-30 °C.

Solubility

Practically insoluble in water (less than 10 mg/L)

Purity

Purity information is available upon request (COA).

Synonym

efavirenz; 154598-52-4; Sustiva; Stocrin; DMP-266

IUPAC/Chemical Name

(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one

InChl Key

XPOQHMRABVBWPR-ZDUSSCGKSA-N

InChl Code

InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/64139;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download